Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHR – Research Report), Palvella Therapeutics (PVLA – Research Report) and Xeris Pharmaceuticals (XERS – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Danaher (DHR)
Morgan Stanley analyst Kallum Titchmarsh reiterated a Buy rating on Danaher on January 28 and set a price target of $270.00. The company’s shares closed last Friday at $219.67.
According to TipRanks.com, Titchmarsh is a 4-star analyst with an average return of
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $266.18, representing a 21.3% upside. In a report issued on January 28, TipRanks – DeepSeek also upgraded the stock to Buy with a $263.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Palvella Therapeutics (PVLA)
Craig-Hallum analyst Albert Lowe maintained a Buy rating on Palvella Therapeutics today. The company’s shares closed last Friday at $76.33.
According to TipRanks.com, Lowe is a 4-star analyst with an average return of
Currently, the analyst consensus on Palvella Therapeutics is a Strong Buy with an average price target of $182.15, implying a 126.6% upside from current levels. In a report issued on January 25, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $95.00 price target.
Xeris Pharmaceuticals (XERS)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Xeris Pharmaceuticals today. The company’s shares closed last Friday at $7.31.
According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of
Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $11.00, which is a 50.7% upside from current levels. In a report issued on January 15, TipRanks – Google also upgraded the stock to Buy with a $8.50 price target.
